Tuesday, November 06, 2012 9:37:50 AM
BMRN:
Thanks for the info/correction. Yeah Aldurazyme I could try blaming lack of sleep but its actually bad memory
.
On Morquio I recall (if you want to trust my memory) the company initially considering an end point of bone growth (rate more so than amount) in something like an 18 month trial as they had data indicating Naglazyme had been shown to increase bone growth. They went with 6MW after the Phase 2 because it seemed like they could do it with a shorter trial.
On the call the lead investigator stressed how it is more than a skeletal disease (there was an analyst call a bit earlier where one doc claimed the drug would only be needed for a short period of time).
Thanks for the info/correction. Yeah Aldurazyme I could try blaming lack of sleep but its actually bad memory
. On Morquio I recall (if you want to trust my memory) the company initially considering an end point of bone growth (rate more so than amount) in something like an 18 month trial as they had data indicating Naglazyme had been shown to increase bone growth. They went with 6MW after the Phase 2 because it seemed like they could do it with a shorter trial.
On the call the lead investigator stressed how it is more than a skeletal disease (there was an analyst call a bit earlier where one doc claimed the drug would only be needed for a short period of time).
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
